Immuncell-LC Boosts Survival in Phase 3 Glioblastoma Trial: A Promising Immunotherapy Advance

Immuncell-LC Shows Promising Survival Benefits in Phase 3 Glioblastoma Trial

GC Cell Corporation has announced positive results from its completed Phase 3 clinical trial evaluating Immuncell-LC (activated T lymphocyte) in combination with temozolomide for patients with newly diagnosed glioblastoma. The multi-center, randomized, open-label study demonstrated significant improvements in both progression-free survival and overall survival compared to temozolomide alone.

The study, which enrolled 180 patients across seven medical centers in South Korea, showed that adding Immuncell-LC to standard temozolomide therapy extended median progression-free survival to 8.1 months compared to 5.4 months in the control group. More importantly, the combination therapy improved median overall survival to 22.47 months versus 16.88 months with temozolomide alone.

How Does This Autologous Cell Therapy Work?

Immuncell-LC is an autologous cell therapy product designed to remove minimal residual cancer cells after surgical removal of brain tumors and prevent relapse. For the treatment, patients' blood was drawn at least two weeks prior to therapy to manufacture the personalized treatment. The product contains 10^9 to 2×10^10 lymphocytes administered intravenously over one hour.

Patients in both study arms received standard chemoradiotherapy with temozolomide for six weeks according to clinical test plans, followed by temozolomide alone for an additional six weeks. The treatment group received 14 administrations of Immuncell-LC alongside the standard regimen.

Study Design and Patient Population

The study population consisted of patients aged 18-70 years with pathologically confirmed glioblastoma who had received surgery (complete or partial extirpation or biopsy) within two weeks prior to enrollment. All patients had a Karnofsky performance scale score greater than 60 and expected survival longer than three months.

Safety profiles were generally comparable between the two groups. Serious adverse events were reported in 31 patients (34.8%) in the control group and 35 patients (38.5%) in the Immuncell-LC group. The most common serious adverse events were convulsion, headache, and brain edema. No unexpected safety signals were identified for the combination therapy.

Efficacy Assessment and Clinical Implications

Enhanced MRI was used to assess progression-free survival by investigators, performed approximately four weeks after chemoradiotherapy and then at regular intervals throughout the 46-month assessment period.

These findings represent a potentially meaningful advancement for glioblastoma patients, who typically face poor prognosis with limited treatment options. The combination of immunotherapy with standard treatment appears to offer improved outcomes in this challenging disease setting.

Summary

GC Cell Corporation's Phase 3 clinical trial evaluating Immuncell-LC in newly diagnosed glioblastoma has demonstrated significant clinical benefits. This multicenter, randomized study conducted across seven South Korean medical centers showed that adding the activated T lymphocyte therapy to standard temozolomide treatment extended median progression-free survival from 5.4 to 8.1 months and improved overall survival from 16.88 to 22.47 months. The autologous cell therapy, which contains 10^9 to 2×10^10 lymphocytes administered intravenously, is designed to eliminate minimal residual cancer cells following tumor resection. Safety profiles remained comparable between treatment arms, with no unexpected adverse events identified. These findings suggest that combining immunotherapy with standard treatment may offer meaningful improvements for glioblastoma patients, who typically face poor prognosis with limited therapeutic options.